Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Curaleaf Q3 Results Drive Down Stock Nearly 5%

By Eric Volkman - Nov 19, 2019 at 7:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company met revenue expectations, but missed slightly on the bottom line.

Shares of marijuana stock Curaleaf Holdings ( CURLF -0.65% ) are down by nearly 5% as of this writing in after-hours trading. This follows the company's post-market release of its Q3 of fiscal 2019 results.

For the quarter, the company booked $61.8 million in total revenue, which was up by 27% on Q2's result and nearly triple the tally in the same period one year ago.

Marijuana leaf atop a plank of wood.

Image source: Getty Images.

Curaleaf, a cannabis company that is very active in the retail segment, said its take from retail and wholesale activities came in at nearly $51 million. That represented a 34% quarter-over-quarter improvement.

The notable increase was due, the company said, to organic growth in its established operations in New York and Florida, plus recent acquisitions in Maryland and Arizona. The recent expansion of dispensaries in the company's home state of Massachusetts also boosted wholesale revenue.

In terms of profitability, Curaleaf managed to widen its gross margin; it came in at 47% from the quarter, an improvement over the previous frame's 40%. The year-ago figure, however, was 55%.

Q3 2019's net loss was $6.8 million, or $0.01 per share. That compares favorably to both the Q2 shortfall of $24.5 million and the Q3 2018 deficit of $33.7 million.

The company's revenue this past quarter basically matched analyst expectations. Curaleaf notched a slight beat on the bottom line, as those prognosticators were collectively modeling a $0.02-per-share loss for the quarter.

Curaleaf is aiming to continue along the growth path. In the press release detailing the results, the company said its "main focus continues to be prudent capital allocation, operational improvement and integration of our pending and closed acquisitions to drive continued strong overall growth and operating leverage."

Like other marijuana stocks, Curaleaf had been going the acquisition route to help bulk up its scale. Its nearly $1 billion deal to buy the Select brand from Cura Partners is still pending, although the arrangement was recently modified. An $875 million deal to purchase multistate dispensary operator Grassroots is also still in the pipeline.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Curaleaf Holdings, Inc. Stock Quote
Curaleaf Holdings, Inc.
$9.23 (-0.65%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.